

Oral presentation

Open Access

## Blood oxygen level-dependent magnetic resonance imaging at 3 Tesla in coronary artery disease: validation using quantitative coronary angiography and cardiovascular magnetic resonance perfusion imaging

Jayant R Arnold<sup>\*1</sup>, Theodoros D Karamitsos<sup>1</sup>, Paul Bhamra-Ariza<sup>2</sup>, Jane M Francis<sup>1</sup>, Nick Searle<sup>1</sup>, Robin P Choudhury<sup>1</sup>, Matthew Robson<sup>1</sup>, Paolo G Camici<sup>2</sup>, Adrian Banning<sup>1</sup>, Stefan Neubauer<sup>1</sup>, Michael Jerosch-Herold<sup>3</sup> and Joseph B Selvanayagam<sup>4</sup>

Address: <sup>1</sup>John Radcliff Hospital, Oxford, UK, <sup>2</sup>Hammersmith Hospital, London, UK, <sup>3</sup>Brigham Women's Hospital, Boston, MA, USA and <sup>4</sup>Flinders Medical Centre, Adelaide, Australia

\* Corresponding author

from 13th Annual SCMR Scientific Sessions  
Phoenix, AZ, USA. 21-24 January 2010

Published: 21 January 2010

*Journal of Cardiovascular Magnetic Resonance* 2010, **12**(Suppl 1):O34 doi:10.1186/1532-429X-12-S1-O34

This abstract is available from: <http://jcmr-online.com/content/12/S1/O34>

© 2010 Arnold et al; licensee BioMed Central Ltd.

### Background

By exploiting the paramagnetic properties of deoxyhemoglobin, blood oxygen level-dependent (BOLD) MRI can be used to determine myocardial oxygenation. In this study involving human subjects, we used BOLD and perfusion MRI at 3 Tesla to investigate the relationship between coronary artery stenosis, myocardial perfusion and tissue oxygenation. We sought (1) to define a threshold for BOLD MRI to identify myocardium subtended by coronary stenosis, and (2) to determine its diagnostic accuracy in patients with suspected CAD.

### Methods

Subjects were studied at 3 Tesla (Trio, Siemens Medical Solutions). Ischemic thresholds for BOLD and first-pass perfusion imaging were determined in 25 patients (age  $61 \pm 7$ ) with known CAD and 20 normal volunteers (age  $53 \pm 7$ ). These thresholds were then applied in a consecutive series of 60 patients with suspected CAD, in whom diagnostic angiography was scheduled to investigate exertional chest pain.

For BOLD MRI, mid-ventricular short-axis images were acquired at rest and stress (4-5 minutes intravenous adenosine,  $140 \mu\text{g}/\text{kg}/\text{min}$ ) using a T2-prepared SSFP sequence (echo time 1.43 ms, repetition time 2.86 ms, T2 preparation time 40 ms, matrix  $168 \times 192$ , slice thickness 8 mm, flip angle  $44^\circ$ ). First-pass perfusion imaging was then performed in the same slice locations following intravenous Gadolinium-DTPA bolus injections ( $0.04 \text{ mmol}/\text{kg}$ , Gadodiamide, Omniscan™, GE Healthcare) using a T<sub>1</sub>-weighted fast gradient echo sequence (echo time 1.04 ms, repetition time 2 ms, voxel size  $2.1 \times 2.6 \times 8 \text{ mm}^3$ ). Absolute quantification of perfusion was performed using model-independent deconvolution. For BOLD analysis, stress signal intensity (SI) was indexed to resting SI using a segmental approach. Quantitative coronary angiography was used to evaluate segmental coronary stenosis: a reduction in luminal diameter of  $> 50\%$  was deemed significant.

### Results

In the validation arm, taking QCA as the gold standard, cut-off values to define ischemic segments were derived for hyperemic myocardial blood flow ( $< 2.1 \text{ ml}/\text{min}/\text{g}$  -

AUC 0.72) and BOLD SI change (<5.2% - AUC 0.64). In the prospective arm, the complete imaging protocol was performed in 57 individuals (age  $61 \pm 9$ , CAD prevalence 68%). On a per subject basis, applying the BOLD SI threshold provided diagnostic accuracy 83%, sensitivity 94% and specificity 56% for the detection of CAD (compared with 84%, 95% and 61%, respectively for perfusion imaging). On a per subject basis, agreement between BOLD and perfusion imaging was 81%.

### Conclusion

BOLD imaging at 3 Tesla is comparable with first-pass perfusion imaging, and yields favorable diagnostic accuracy in the detection of significant CAD.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

